CHICAGO, Ill., June 2, 2008 (PRIME NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that veltuzumab (or “hA20"), the Company’s humanized anti-CD20 antibody, produced a relatively high complete response rate of 27% in patients with follicular lymphoma, and that such results were achieved even when given at doses about 75% lower than rituximab’s approved dose of 375 mg/m2.
